Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 1703749-62-5
- Molecular formula
- C49H68[177Lu]N9O16
- Molecular weight
- 1216.1 g/mol
- Drug class
- Therapeutic radiopharmaceuticalprostate-specific membrane antigen (PSMA)-targeted radioligand therapy
- Mechanism of action
- A small-molecule ligand binds with high affinity to PSMA on prostate cancer cells and delivers beta-minus radiation from lutetium-177. The emitted radiation induces DNA damage in targeted and nearby cells, potentially leading to cell death.
- Indications / reported uses
- Treatment of adults with PSMA-positive metastatic prostate cancer under the applicable product label; patient selection and approved treatment setting depend on prior androgen-receptor pathway therapy and taxane exposure.
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a · https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto · https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy